Clin Oncol | Volume 2, Issue 1 | Mini Review | Open Access
Line Tarpgaard1, SofieOtzen Bagger2, Per Pfeiffer1, Nils Brünner2 and Jan Stenvang2*
1Department of Oncology, Odense University Hospital, Denmark
2Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
*Correspondance to: Jan StenvangFulltext PDF
Chemotherapy resistance remains a major clinical problem in the current treatment of cancer patients and chemotherapy resistance almost inevitably occursin metastatic cancer patients.In colorectal cancer patients, the response rates to first line chemotherapy therapy is approximately 50%, dropping to approximately 10-20% in second line treatment and no standard third line treatment exists. Thus, there is an obvious and acute need for novel drugs to increase response rates. Here, we focus on the promising idea of repurposing existing drugs in clinical trials with chemotherapy resistant colorectal cancer patients and suggest a general clinical trial design that could be employed to test repurposed drugs.
Tarpgaard L, Bagger SO, Pfeiffer P, Brünner N, Stenvang J. Tarpgaard et al is: Repurposing of Drugs in Chemotherapy Resistant Colorectal Cancer. Clin Oncol. 2017; 2: 1382.